Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (76)

III-01Giulia Lestini

Model-based optimal robust design in pharmacometrics

Thursday 10:05-11:30

III-02Lia Liefaard

Mixed effects modelling of dose-response cough count data

Thursday 10:05-11:30

III-03Andreas Lindauer

Time-to-seizure modeling of the antiepileptic drug lacosamide used in monotherapy

Thursday 10:05-11:30

III-04Ling Xue

Theory based PK-PD of S- and R-warfarin: influence of body size, composition and genotype

Thursday 10:05-11:30

III-05

Population pharmacokinetic and pharmacodynamic (PK/PD) modelling of emerging artemisinin resistance in Southern Myanmar

Thursday 10:05-11:30

III-06Kurt Long

Identification of causal pathways determining the relationship between pathogen-specific infection and impaired growth among children < 59 months in Mirzapur, Bangladesh

Thursday 10:05-11:30

III-07Dominik Lott

Population pharmacokinetics of the selective S1P1 receptor modulator ponesimod

Thursday 10:05-11:30

III-08

A Novel Mechanistic Approach to Predict the Steady State Volume of Distribution (Vss) using the Fick-Nernst-Planck Equation

Thursday 10:05-11:30

III-09Sreenath M Krishnan

Population modeling of uni- and three- dimensional and density-based tumor measurements in gastro-intestinal stromal tumor (GIST) patients treated with imatinib

Thursday 10:05-11:30

III-10Vincent Madelain

Favipiravir pharmacokinetics in non-human primates: insights for future efficacy studies against hemorrhagic fever viruses

Thursday 10:05-11:30

III-11Mats Magnusson

Population PKPD Analysis of CD4 and ACR Response after SC Administration of Tregalizumab to Patients with Rheumatoid Arthritis

Thursday 10:05-11:30

III-12Adedeji Majekodunmi

Mechanistic modelling of naive CD4+ T cell homeostasis in HIV-infected children on anti-retroviral therapy

Thursday 10:05-11:30

III-13Victor Mangas-Sanjuan

Exploring Inter-study variability in the context of modeling unperturbed xenograft data

Thursday 10:05-11:30

III-14Vikash Mansinghka

BayesDB Marcro Indicator Explorer ensemble models for growth outcome country phenotyping

Thursday 10:05-11:30

III-15Ben Margetts

Modelling Severe Human Cytomegalovirus Infections in an Immunocompromised Paediatric Patient Population

Thursday 10:05-11:30

III-16Amelie Marsot

Population pharmacokinetic model of delta-9-tetrahydrocannabinol (THC) in cannabis occasional smokers

Thursday 10:05-11:30

III-17Lisa Martial

Population PK model and pharmacokinetic target attainment of micafungin in ICU patients

Thursday 10:05-11:30

III-18

Modelling based methods to account for dropout in xenograft experiments

Thursday 10:05-11:30

III-19Jean-Marie Martinez

Modelling and simulation of alirocumab – Part 1: Population pharmacokinetic analysis using a Michaelis-Menten approximation of the target-mediated drug disposition model

Thursday 10:05-11:30

III-20Paolo Mazzei

Population exposure-response modeling of oral nepadutant administration in infants with colic

Thursday 10:05-11:30

III-21Litaty Céphanoée Mbatchi

Pharmacokinetics modelling of temsirolimus and its active metabolite

Thursday 10:05-11:30

III-22Johanna Melin

Semi-mechanistic modelling of the nonlinear hydrocortisone pharmacokinetics to enable extrapolation into paediatric patients

Thursday 10:05-11:30

III-23Evgeny Metelkin

Development of immune responce template forsystems pharmacology modeling of immunotherapy in oncology

Thursday 10:05-11:30

III-24Jonathan Mochel

Pharmacodynamics of the renin-angiotensin aldosterone system and blood pressure in relation to food intake in dogs

Thursday 10:05-11:30

III-25Shuhua Hu

Use of interim analysis to improve efficiency of clinical trial simulations in treatment comparison trial design studies

Thursday 10:05-11:30

III-26Pablo Morentin Gutierrez

A population pharmacokinetic-pharmacodynamic model for AZD7687: Effects on plasma triacylglycerol after oral lipid tolerance test

Thursday 10:05-11:30

III-27Michael Morimoto

A quantitative physiologic model of the interaction of nutrition and infection in determining the energy available for growth

Thursday 10:05-11:30

III-28Samer Mouksassi

Primary microcephaly: do all roads lead to Rome?

Thursday 10:05-11:30

III-29Morris Muliaditan

Prediction of the exposure of anti-tuberculosis drugs in lung tissue: implications for dose selection

Thursday 10:05-11:30

III-30Zufar Muliukov

Modeling the effect of ranibizumab on central retinal thickness in patients with wet age-related macular degeneration

Thursday 10:05-11:30

III-31Silke Gastine

Population Pharmacokinetics of Voriconazole in pediatric cancer patients – assessing new dosing strategies

Thursday 10:05-11:30

III-32C.J. Musante

The International Society of Pharmacometrics’ Special Interest Group on Quantitative Systems Pharmacology: Developing a community and advancing a field

Thursday 10:05-11:30

III-33Karin Nelander

Longitudinal dose-response modelling as primary analysis of a clinical study

Thursday 10:05-11:30

III-34Xavier Nicolas

Modelling and simulation of alirocumab – Part 2: Population pharmacokinetic/pharmacodynamic analysis using an indirect response model to link drug concentrations with LDL-C

Thursday 10:05-11:30

III-35Jaeseong Oh

Simultaneous population pharmacokinetic analysis of VVZ-149 and its active metabolite in healthy volunteers

Thursday 10:05-11:30

III-36Boram Ohk

Population Pharmacokinetic modeling of Tacrolimus in Healthy Korean Subjects

Thursday 10:05-11:30

III-37Andrés Olivares-Morales

Combining population with physiologically-based pharmacokinetic (PBPK) models for oral drug absorption: Predicting the segmental bioavailability differences of R-oxybutynin and its main metabolite using a middle out approach.

Thursday 10:05-11:30

III-38Per Olsson Gisleskog

Predicting the effects of combining broadly neutralizing antibodies (bNabs) binding to different HIV viral epitopes

Thursday 10:05-11:30

III-39Mohamed Omari

Modelling of glucose-insulin metabolism and its effect on the estrous cycle in bovine

Thursday 10:05-11:30

III-40Sean Oosterholt

Model-based extrapolation and dosing recommendation for raxibacumab in children from birth to <18 years of age

Thursday 10:05-11:30

III-41Stine Timmermann Ottesen

Analysing the contribution to receptor occupancy from active metabolites

Thursday 10:05-11:30

III-42- -

Delineation of the treatment effect of methotrexate when used in combination therapy for rheumatoid arthritis

Thursday 10:05-11:30

III-43Theodoros Papathanasiou

Population modelling of the synergistic effects of morphine and gabapentin in the rat: a response surface approach

Thursday 10:05-11:30

III-44Zinnia Parra-Guillen

Pharmacokinetic analysis of midazolam and caffeine as probe drugs for cytochrome phenotyping in erlotinib treatment

Thursday 10:05-11:30

III-45Sophie Peigné

Optimal design in the analysis of a clinical study in paediatric population

Thursday 10:05-11:30

III-46Nathalie Perdaems

PK/PD modelling: a usefull tool to train people to better design in vivo chronic study in ob/ob mice

Thursday 10:05-11:30

III-47Belén Pérez Solans

Markov model for tumor shrinkage effects of combination therapy in non-metastatic gastric cancer patients

Thursday 10:05-11:30

III-48Alejandro Pérez-Pitarch

Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes Mellitus: Modelling Rate and Severity of Hypoglycemic Events

Thursday 10:05-11:30

III-49Carlos Perez-Ruixo

Population pharmacokinetics and antiviral efficacy in neonatal lambs: evidence of rapid maturation and auto-induction drug effect in metabolic clearance

Thursday 10:05-11:30

III-50

Early phase dose-finding designs for bridging studies in pediatrics

Thursday 10:05-11:30

III-51Séverine Petitprez

Population pharmacokinetic meta-analysis of seven antiretroviral drugs

Thursday 10:05-11:30

III-52Tatiana Petukhova

Population PK modeling of RPH-104, novel optimized IL-1 beta trap, and assessment of the immunogenicity effect on pharmacokinetics

Thursday 10:05-11:30

III-53Thomas Peyret

A mechanistic maternal-fetal growth energy budget model

Thursday 10:05-11:30

III-54

Population Pharmacokinetics of the Novel Antimalarial OZ439

Thursday 10:05-11:30

III-55Chiara Piana

A novel model-based methodology for the evaluation of abuse potential

Thursday 10:05-11:30

III-56Philippe Pierrillas

From mouse to human: comparison of interspecies translational strategies using integrative semi-mechanistic PK-PD models and PBPK-PD modeling to forecast efficacious clinical dose

Thursday 10:05-11:30

III-57Teun Post

Application of a Shiny Workflow in Cardiovascular Effects Evaluations

Thursday 10:05-11:30

III-58Manuel Prado-Velasco

Bridging the gap between open and specialized modelling tools in PBPK/PK/PD with PhysPK/EcosimPro modelling system: PBPK model of methotrexate and 6-mercaptopurine in humans with focus in reusability and multilevel modelling features

Thursday 10:05-11:30

III-59Tim Preijers

In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients

Thursday 10:05-11:30

III-60Claire Pressiat

Population pharmacokinetics of cotrimoxazole In West African HIV-infected children

Thursday 10:05-11:30

III-61Angelica Quartino

Comparisons of Multiple Exposure-Response Methodologies in Oncology

Thursday 10:05-11:30

III-62Rachel Rose

Development of a novel multi-compartment granuloma model to predict local drug distribution and its impact on pharmacodynamics and disease progression in tuberculosis.

Thursday 10:05-11:30

III-63

Development of a PBPK approach to predict the pharmacokinetics in patients with sepsis

Thursday 10:05-11:30

III-64Christian Hove Claussen

Automated modeling workflow with LaTeX: using the new Pfizer Report Tool

Thursday 10:05-11:30

III-65Isabel Reinecke

Changes in endogenous estradiol concentrations explain fluctuations in levonorgestrel (LNG) concentrations during continuous treatment with LNG releasing intravaginal rings

Thursday 10:05-11:30

III-66Su-jin Rhee

A population pharmacokinetic analysis of levetiracetam in patients with epilepsy

Thursday 10:05-11:30

III-67Sophie Rhodes

Previous BCG vaccination associated with variation in Mycobacterial-specific immune response: a modelling study

Thursday 10:05-11:30

III-68Jakob Ribbing

Predicting reductions in chronic obstructive pulmonary disease (COPD) exacerbations from FEV1 – A model-based meta-analysis of literature data from controlled randomized clinical trials

Thursday 10:05-11:30

III-69Camille Riff

First population pharmacokinetic model of lidocaine tumescent anaesthesia in women undergoing breast cancer surgery

Thursday 10:05-11:30

III-70Clémence Rigaux

Parasitemia clearance modeling following Ferroquine administration in P. Falciparum infected patients

Thursday 10:05-11:30

III-71Christelle Rodrigues

Population pharmacokinetics of oxcarbazepine and its 10-monohydroxy derivative in epileptic children

Thursday 10:05-11:30

III-72Stefan Roepcke

Model-based analysis of monkey PK and PD data of a therapeutic cell depleting human monoclonal antibody – Preparing for clinical trials

Thursday 10:05-11:30

III-73Amit Roy

Evaluating effectiveness of case-matching for exposure-response analysis

Thursday 10:05-11:30

III-74Yue Ruan

Bayesian hierarchical model of glucose-insulin regulation over 12-week home use of closed-loop insulin delivery

Thursday 10:05-11:30

III-75Muhammad Waqas Sadiq

Acute tolerance and rebound modelling with competitive interaction of mineralcorticoid driven urinary sodium excretion effects in the rat

Thursday 10:05-11:30

III-76Richard Pugh

Data Science & Big Data: An Opportunity or a threat for Pharmacometrics?

Thursday 10:05-11:30